LLY · Discounted Cash Flow Valuation

Eli Lilly DCF Valuation: Intrinsic Value Calculator

Eli Lilly and Company (LLY) DCF model with live financials. See the pre-loaded intrinsic value estimate below, then adjust growth and discount rate assumptions in the full calculator.

DCF Snapshot

Current Price$939.47

Market Cap$840.8B

TTM Free Cash Flow$2.0B

Intrinsic Value / Share$85.37

Upside / Downside-90.9%

Assumptions

FCF Growth Rate15%

Discount Rate (WACC)9.5%

Terminal Growth3%

Projection Period10 years

These are conservative starting assumptions. Adjust them in the full calculator to test your own thesis.

What Drives Eli Lilly's DCF

Eli Lilly's DCF is dominated by its GLP-1 franchise — Mounjaro (tirzepatide) for diabetes and Zepbound for obesity represent a potential $50B+ combined revenue opportunity in a market with massive unmet demand. Revenue is growing 30%+ as manufacturing capacity ramps to meet demand. Key assumptions: GLP-1 revenues scale toward $40B+ by 2030, pipeline assets in Alzheimer's (donanemab) and oncology provide additional growth vectors, and gross margins remain above 80% given the pricing power in the obesity therapeutic category.

Adjust these assumptions in the full DCF calculator →Get the full analysis →

More tools & guides

DCF Calculator

Run a full DCF on any ticker with live data

DCF Analysis Guide

The complete guide to building and stress-testing a DCF model

Intrinsic Value Calculator

Compare DCF, earnings power, and asset-based valuations side by side